Anavex Life Sciences Corp (AVXL)

[falconer66a]

Population Fractions with Favorable Genetics Yet Unknown

I’ve seen no occurrence data, related to any of the various genomic traits associated with Anavex 2-73 efficacy. Study of the genes of the people in the early Australian study (just 32 people) revealed particular genetic tendencies toward Anavex 2-73 efficacy. In short, there are coordinated clinical and genetic data showing the drug works with particular efficacy in people with particular genes.

So, what if only 10% of people with Alzheimer’s have genetics that predispose them to effective treatment with Anavex 2-73? If that were the case (I don’t see that it will be), the drug would still gain rather immediate FDA approval, for those many millions with such genomic profiles. Anavex Life Sciences Corp would have a still large, profitable market for it’s new drug.

Anavex 2-73 re-connects and supports proper, normalized functions of mitochondria and the associated endoplasmic reticula. It may well be that those with advanced, chronic cases of Alzheimer’s have their neurons so diseased the Anavex 2-73 simply can’t put things back together again. Too far gone. It’s very reasonable to presume that Alzheimer’s progresses to states of such profound cellular dysfunction that the Anavex drug (or any other) simply cannot put things back together again.

Not yet tested (but may be revealed to some extent in the new Australian study) is the effect of early administration of Anavex 2-73. Most likely, earlier Anavex treatment is better treatment. Instead of waiting until patients have moderately advanced stages of the disease, prescribe and administer the drug just as soon as the first symptoms of dementia appear. Then, even at low intra-cellular concentrations, Anavex 2-73 can “fix things” before they become irreparable. Prophylaxis; prevention, at an early, even pre-symptomatic stage.

A number of dosing matters need to be determined. When should dosing begin? What symptoms should dictate when a physician prescribes the drug? What should be the dosing regimen: frequencies, dosing quantities? Might more advanced cases of Alzheimer’s best respond to IV dosings?

All, yet to be determined. No matter. With any clinical efficacies discovered in the upcoming Australian study, Anavex Life Science Corp has a great future, along with its shareholders and client patients.